

**Atty Docket No.: 3284/1235 (Serial No.: 09/963,875)**

**Inventors: Habener, et al.**

**Filed: September 26, 2001**

**Amendment Response to Office Action**

The following Listing of the claims will replace all prior versions and all prior listings of the claims in the present application.

Claims 1-38, 42, 44-73, 75, 76, 80, 82 and 84 are cancelled. New claims 85 through 108 are added.

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)

29. (Canceled)

30. (Canceled)

31. (Canceled)

32. (Canceled)

33. (Canceled)

34. (Canceled)

35. (Canceled)

36. (Canceled)

37. (Canceled)

38. (Canceled)

39. (Currently Amended) An isolated composition comprising at least 30%, [[isolated]] nestin-positive human pancreatic or liver stem cells that [[is]]are not [[a]] neural stem cells.

40. (Currently Amended) The isolated composition of any one of claims 39 and 85 through 94, wherein said [[isolated]] nestin-positive human pancreatic or liver stem cells [[of claim 39, wherein said cell is]] are also GLP-1R-positive.

41. (Currently Amended) An isolated comprising at least 30% [[isolated,]] GLP-1R-positive human pancreatic or liver stem cells that [[is]] are not [[a]] neural stem cells.

42. (Canceled)

43. (Currently Amended) The isolated composition of any one of claims 39 and 85 through 94, wherein said [[isolated]] stem cells [[of claim 39 or 41 that]] differentiate[[s]] to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

44. (Canceled)

45. (Canceled)

46. (Canceled)

47. (Canceled)

48. (Canceled)

49. (Canceled)

50. (Canceled)

51. (Canceled)

52. (Canceled)

53. (Canceled)

54. (Canceled)

55. (Canceled)

56. (Canceled)

57. (Canceled)

58. (Canceled)

59. (Canceled)

60. (Canceled)

61. (Canceled)

62. (Canceled)

63. (Canceled)

64. (Canceled)

65. (Canceled)

66. (Canceled)

67. (Canceled)

68. (Canceled)

69. (Canceled)

70. (Canceled)

71. (Canceled)

72. (Canceled)

73. (Canceled)

74. (Currently Amended) A pharmaceutical composition comprising the [[isolated stem cell]] isolated composition of claim 39 [[or]] admixed with a physiologically compatible carrier.

75. (Canceled)

76. (Canceled)

77. (Currently Amended) An [[The]] isolated nestin-positive, GLP-1R-positive or nestin and GLP-1R-positive human pancreatic stem cell [[of claim 39,]] isolated by [[the method of claim 75]]:

a) removing a pancreatic islet from a donor;

b) removing cells from said pancreatic islet wherein said islet comprises a plurality of cell types comprising stem cells; and

c) separating said stem cells from said plurality of cells.

78. (Previously Presented) The isolated stem cell of claim 77 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

79. (Previously Presented) A pharmaceutical composition comprising the isolated stem cell of claim 77 admixed with a physiologically compatible carrier.

80. (Cancelled)

81. (Currently Amended) The isolated [[stem cell]] composition of claim 41, wherein said stem cells [[that]] differentiate[[s]] to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

82. (Cancelled)

83. (Currently Amended) A pharmaceutical composition comprising the isolated [[stem cell]] composition of claim 41 admixed with a physiologically compatible carrier.

84. (Cancelled)

85. (New) An isolated composition comprising at least 40%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

86. (New) An isolated composition comprising at least 50%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

87. (New) An isolated composition comprising at least 60%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

88. (New) An isolated composition comprising at least 70%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

89. (New) An isolated composition comprising at least 80%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

90. (New) An isolated composition comprising at least 85%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

91. (New) An isolated composition comprising at least 90%, nestin-positive human pancreatic or

liver stem cells that are not neural stem cells.

92. (New) An isolated composition comprising at least 95%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

93. (New) An isolated composition comprising at least 98%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

94. (New) An isolated composition comprising at least 99%, nestin-positive human pancreatic or liver stem cells that are not neural stem cells.

95. (New) An isolated composition comprising at least 40%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

96. (New) An isolated composition comprising at least 50%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

97. (New) An isolated composition comprising at least 60%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

98. (New) An isolated composition comprising at least 70%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

99. (New) An isolated composition comprising at least 80%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

100. (New) An isolated composition comprising at least 85%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

101. (New) An isolated composition comprising at least 90%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

102. (New) An isolated composition comprising at least 95%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

103. (New) An isolated composition comprising at least 98%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

104. (New) An isolated composition comprising at least 99%, GLP-1R-positive human pancreatic or liver stem cells that are not neural stem cells.

105. (New) An isolated, nestin-positive, GLP-1R positive or nestin and GLP-1R-positive human pancreatic or liver stem cell that is not a neural stem cell, wherein said cell is isolated from a pancreatic islet.

106. (New) The isolated stem cell of claim 105 that differentiates to form at least one of: insulin-producing beta cells, glucagon-producing alpha cells; pseudo-islet like aggregates; and hepatocytes.

107. (New) A pharmaceutical composition comprising the stem cell of claim 105, admixed with a physiologically compatible carrier.

108. (New) A pharmaceutical composition comprising the isolated composition of claim 40, admixed with a physiologically compatible carrier.